Europeiska unionen - svenska - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. för vidare information om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. för ytterligare information om her2-status, se avsnitt 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, non-small cell lung - antineoplastiska medel - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklid imaging - diagnostiska radioaktiva läkemedel - detta läkemedel är endast för diagnostisk användning. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - imatinibmesilat - filmdragerad tablett - 600 mg - imatinibmesilat 717 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

2care4 aps - paroxetinhydroklorid (vattenfri) - filmdragerad tablett - 10 mg - paroxetinhydroklorid (vattenfri) 11,1 mg aktiv substans; mannitol hjälpämne - paroxetin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - paroxetinhydroklorid (vattenfri) - filmdragerad tablett - 10 mg - mannitol hjälpämne; paroxetinhydroklorid (vattenfri) 11,1 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - paroxetinhydroklorid (vattenfri) - filmdragerad tablett - 10 mg - mannitol hjälpämne; paroxetinhydroklorid (vattenfri) 11,1 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - paroxetinhydroklorid (vattenfri) - filmdragerad tablett - 10 mg - paroxetinhydroklorid (vattenfri) 11,1 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

2care4 aps - paroxetinhydroklorid (vattenfri) - filmdragerad tablett - 10 mg - paroxetinhydroklorid (vattenfri) 11,1 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

hexal a/s - paroxetinhydroklorid (vattenfri) - filmdragerad tablett - 10 mg - paroxetinhydroklorid (vattenfri) 11,1 mg aktiv substans; mannitol hjälpämne - paroxetin